1	Does maternal immunization blunt the effectiveness of pertussis vaccines in
2	infants? A systematic review and modeling study
3	
4	Michael Brigaª, Elizabeth Goultª, Tobias S Brett ^{b,c} , Pejman Rohani ^{b,c} , Matthieu Domenech
5	de Cellès ^a
6	
7	^a Infectious Disease Epidemiology Group, Max Planck Institute for Infection Biology,
8	Berlin, Germany
9	^b Odum School of Ecology, University of Georgia, Athens, GA 30602
10	cCenter of Ecology of Infectious Diseases, Athens, GA 30602،

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

11 Abstract

A key goal of pertussis control is to protect infants too young to be vaccinated, the age 12 13 group most vulnerable to this highly contagious respiratory infection. In the last decade, 14 maternal immunization has been deployed in many countries, successfully reducing 15 pertussis in this age group. Because of immunological blunting, however, this strategy may erode the effectiveness of primary vaccination at later ages. Here, we systematically 16 reviewed the literature on the relative risk (RR) of pertussis after primary immunization 17 of infants born to vaccinated vs. unvaccinated mothers. The four studies identified had 18 19 \leq 6 years of follow-up and large statistical uncertainty (meta-analysis weighted mean RR: 20 0.71, 95% CI: 0.38–1.32). To interpret this evidence, we designed a new mathematical model with explicit blunting mechanisms and evaluated maternal immunization's short-21 22 and long-term impact on pertussis transmission dynamics. We show that transient dynamics can mask blunting for at least a decade after rolling out maternal immunization. 23 24 Hence, the current epidemiological evidence may be insufficient to rule out modest reductions in the effectiveness of primary vaccination. Irrespective of this potential 25 26 collateral cost, we predict that maternal immunization will remain effective at protecting unvaccinated newborns, supporting current public health recommendations. 27

28

29 Introduction

30

Pertussis is a highly transmissible respiratory infection that is primarily caused by the bacterium *Bordetella pertussis*^{1,2}. Pertussis was a leading cause of childhood mortality until intense immunization programs, from the 1940s onwards, reduced pertussis notifications by over 90% in many countries^{3,4}. However, in the last couple of decades, pertussis has re-emerged in many populations with high long-term immunization coverage, for reasons which remain highly debated⁵.

37

38 Newborns are the age group most vulnerable to pertussis. In high-income countries, 39 pertussis-related hospitalization rates in infants under 6 months are between 100 and 40 100,000 per year⁶, and data from the US⁷ and Australia⁸ show that over 60% of pertussis-41 associated hospitalizations are under one year old. To reduce the burden of pertussis in vulnerable newborns, since 2012, many countries have introduced maternal 42 43 immunization—*i.e.*, vaccinating pregnant individuals, usually during the second or third trimester of pregnancy, with a low-dose tetanus toxoid, diphtheria toxoid, and acellular 44 pertussis (Tdap) vaccine. In 2015, the World Health Organization (WHO) issued an 45 official recommendation for maternal immunization with acellular vaccines against 46 pertussis (based on studies with acellular primary immunization)⁹, and by 2020 maternal 47 48 immunization against pertussis was recommended in 55 countries¹⁰.

49

Maternal immunization is highly effective at protecting newborns, with estimates of 50 reductions in the risk of pertussis infection ranging from 70 to 95%^{8,11-17}. However, the 51 52 downstream consequences of maternal immunization, when infants receive their routine pertussis vaccines, are poorly understood. Specifically, there has been long-standing 53 54 concern regarding potential immunological blunting, *i.e.*, the interference of maternally transferred antibodies with the infant immune response^{18–20}. Indeed, several studies and 55 meta-analyses have shown that, after infants received their primary immunization, the 56 antibody concentrations against several pertussis antigens were reduced by 30% to 60% 57 in infants from vaccinated mothers relative to infants from unvaccinated mothers²¹⁻²⁴. 58 59 Similarly, the avidity of pertussis antibodies is reduced in infants from vaccinated mothers²⁵. Interestingly, the blunting response following maternal pertussis 60 61 immunization appears to be heterologous, also causing decreased antibody

concentration after infants received a polio vaccine²⁶ and the blunting response also
applies to other vaccines that contain (modified) diphtheria or tetanus toxins as carrier
proteins, such as pneumococcus conjugate vaccines ^{22,26}.

65

While immunological blunting is well documented, because the first maternal 66 67 immunization programs were implemented in 2012, the long-term consequences of blunting on vaccine effectiveness (VE) and the ensuing epidemiology of pertussis remain 68 69 difficult to evaluate. Here, we assess the epidemiological evidence for blunting and 70 estimate the long-term consequences of maternal immunization in three steps. First, we 71 perform a systematic review of the literature for estimates of the impact of maternal 72 immunization on the relative risk of pertussis after primary pertussis immunization in 73 infants from vaccinated mothers relative to unvaccinated mothers. Second, we extend a previously validated model of pertussis immunization^{4,27} to simulate over several 74 decades the short- and long-term epidemiological impact of maternal immunization with 75 76 various levels of blunting and maternal immunization coverages on the age-specific time series of pertussis incidence. Third, to identify possible levels of blunting and the 77 consequences of maternal immunization, we match the relative risk estimates obtained 78 from the systematic review with those obtained from the modeling study. 79

80

81 Results

82

A systematic review of empirical studies on the relative risk of pertussis after maternal and
infant primary immunization

85

We identified 374 peer-reviewed articles and, after removing 146 duplicate records, we screened 228 abstracts for a mention of maternal immunization with either a number of cases, an odds ratio or a relative risk of pertussis and/or effectiveness of a pertussis vaccine (Fig. 1). Based on these criteria, we identified and retrieved 69 articles that might contain information (Table S4).

91

92 Our search identified four studies that reported five estimates of the relative risk of 93 pertussis in infants from vaccinated versus unvaccinated mothers and that specified the 94 dose of infant primary immunization (Fig. 1, Fig. 2, Table S1). Two studies were carried

95 out in the UK, one in Australia, and one in California, US. In all studies, maternal immunization coverage was low right after the implementation of maternal 96 97 immunization but increased to reach >70% (Table S1). The studies' follow-up times 98 ranged from 2 to 6 years (Table S1). At the first dose of infant primary immunization, these studies showed a weighted mean RR of 0.26 (Fig. 2, 95% CI: 0.11-0.67). At the 99 100 second dose of infant primary immunization, the RR increased to a weighted mean of 0.73 (Fig. 2, 95% CI: 0.39–1.34) and this was very similar to the weighted mean RR at the third 101 102 dose of infant primary immunization which had a value of 0.71 (Fig. 2, 95% CI: 0.38-103 1.32).

104

105 The model recapitulates the historical trends of pertussis, with a resurgence caused by a106 honeymoon effect

107

To interpret the RR estimates and assess the short- and long-term impact of blunting on 108 109 pertussis transmission dynamics, we extended an empirically validated model of pertussis epidemiology^{4,27}, to incorporate maternal immunization and its dual effects of 110 protecting unvaccinated newborns and blunting vaccine effectiveness after infant 111 primary immunization. To assess the historical impact of routine immunization in infants, 112 we first examined the trends in overall incidence and age-specific susceptibility. Infant 113 114 immunization induced a strong decrease in pertussis incidence but was followed by a rebound with a gradual buildup of susceptible individuals in adult age groups until a new 115 equilibrium—with lower incidence than in the pre-vaccine era—was reached several 116 decades later (Fig. 3 A & B). As previously demonstrated in the US, this resurgence was 117 118 explained as an "end-of-honeymoon" effect, a predictable consequence of incomplete immunization with imperfect but highly effective vaccines. Hence, our model 119 120 recapitulated the historical dynamics of pertussis in the US, characterized by a 121 resurgence and shift of infections to adolescent and adult age groups⁴.

122

123 Transient dynamics after the start of maternal immunization

124

Second, we examined the impact of maternal immunization, which we introduced 100years after the rollout of infant immunization, to disentangle the consequences of the two

127 immunization programs. Maternal immunization had the intended effect of decreasing

susceptibility to infection in unvaccinated newborns aged 0-2 months (Fig. 3B). 128 129 However, after the rollout of maternal immunization, the model predicted a transient phase with lower pertussis incidence, lasting at least 5 years and followed by a rebound 130 131 (Fig. 4A). In newborns, pertussis incidence was lower after the start of maternal immunization relative to before, but the benefit of maternal immunization was larger in 132 133 a scenario without blunting than in a scenario with blunting (Fig. 4A). Thus, maternal immunization was predicted to be effective at protecting unvaccinated newborns, with 134 135 benefits by far outweighing any possible blunting-mediated increases in incidence.

136

By contrast, in the second age class of infants aged 3–18 months, (*i.e.*, after receipt of the 137 primary pertussis immunization), maternal immunization was followed by a decrease of 138 139 pertussis incidence, but only when blunting was low (<10%, Fig. 4B). At higher levels of 140 blunting, pertussis incidence was predicted to increase relative to before the start of maternal immunization (Fig. 4B). Irrespective of the simulated blunting level, the second 141 142 age class also showed a clear transient phase, lasting at least 5 years (Fig. 4B). During this transient phase, pertussis incidence was first predominantly driven by infants from 143 unvaccinated mothers (Fig. 4C), followed later on by incidence in infants from vaccinated 144 mothers, who dominated once incidence had reached equilibrium (Fig. 4D). These 145 dynamics persisted in children up to 5 years of age, but dissipated by age 10 years, after 146 147 which pertussis incidence remained low and the effects of both maternal immunization 148 and blunting on pertussis incidence were negligible (Fig. S3).

149

150 Comparison with empirical estimates suggests that blunting cannot be ruled out

151

Lastly, we estimated the impact of blunting on the RR of pertussis in vaccinated infants 152 born to mothers vaccinated during pregnancy. In newborns, our simulations show that 153 154 estimates of the effectiveness of maternal immunization (*i.e.*, based on incidence) have a transient phase in a direction consistent with those deduced from the transient incidence 155 dynamics: the effectiveness of maternal immunization was high at first but decreased 156 with time, and equilibrium values were reached only after a transient phase that lasted 157 158 at least a decade (Fig. 5A). Hence, ignoring the transient dynamics results in an overestimation of the effectiveness of maternal immunization, an effect most pronounced 159 160 during the first decade after implementation.

161

162 As expected, in the second age class of infants aged 3–18 months, (*i.e.*, after receipt of the 163 primary pertussis immunization), blunting resulted in RR equilibrium values above 1 (i.e., 164 a higher risk of pertussis in infants born to vaccinated mothers relative to unvaccinated mothers), which increased with the input blunting strength. However, these risks were 165 166 reached only after a transient phase that lasted more than a decade (Fig. 5B). During this transient phase, even in scenarios with blunting, the RR was initially far below 1 and 167 gradually increased after the start of maternal immunization. Hence, ignoring these 168 169 transient dynamics and assuming that an RR of 1 indicates no blunting may result in overestimating the effectiveness of maternal immunization in both unvaccinated 170 171 newborns and vaccinated infants (Fig. 5B). It is noteworthy that the transient phase for 172 the estimation of RR (Fig. 5 A & B) is longer than for the incidence (Fig. 4 A & B). This is 173 because RR (and hence VE) are cumulative estimates instead of instantaneous estimates 174 such as incidence (Fig. S4). Interestingly, depending on the contact matrix, the incidence during the transient phase showed oscillating dynamics, which increases the variability 175 between estimates after 3, 6, or even 10 years (Figs. S12, S13), but these oscillations 176 disappeared in the RR estimates (Figs. S14, S15), likely thanks to their cumulative nature. 177 Interestingly, after the transient phase, a scenario without blunting resulted in RRs below 178 1, due to residual protection from maternal antibodies in infants who were vaccinated 179 180 but in whom the vaccine did not take. This result suggests that the usual assumption that an RR of 1 indicates no blunting may be too optimistic. 181

182

Comparing our model predictions with the results of epidemiological studies, all current 183 empirical RR estimates fell well within the transient phase of our simulations (Fig. 5C). 184 185 Demographic stochasticity accounted for some of the variability in the predicted RR (Fig. 186 5B), but observation noise due to small sample sizes was by far the largest source of 187 uncertainty (Fig. 5C). Inspecting the overlap between confidence intervals, all the empirical estimates were consistent with blunting, even though two estimates (in the UK 188 and California) were also consistent with no blunting. Hence, according to our 189 190 simulations, current empirical studies cannot yet detect the eventual epidemiological 191 consequences of blunting (Fig. 5B), because of the transient RR dynamics following the rollout of maternal immunization. Hence, the model-data comparison suggests that 192

193 current empirical RR estimates cannot rule out a modest level of blunting of infant194 primary immunization (Fig. 5C).

195

196 Sensitivity analyses

197

To assess the robustness of our results, we conducted a range of sensitivity analyses with 198 different hypotheses regarding model parameters, such as the coverage of maternal and 199 infant immunization, the average duration of maternal protection, age-specific contact 200 201 patterns, the age of primary immunization, and the basic reproduction number). To 202 assess the consequences of non-pharmaceutical interventions (NPIs) during the COVID-203 19 pandemic, we further simulated scenarios with transient reductions in vaccine 204 coverage and pertussis transmission. In our simulations, variation in these parameters 205 sometimes had a substantial impact on pertussis incidence, e.g., Figs. S7, S9, S11, and S13. However, our conclusions about blunting were robust in all the sensitivity analyses, and 206 207 the results presented in Figs. S5 to S34 were consistent with those presented in Fig. 4 and 208 Fig. 5.

209

The sensitivity analyses revealed a few noteworthy results. First, a considerable 210 reduction of the blunting effect on pertussis incidence was predicted when delaying the 211 212 age at the start of the infant's primary immunization by a few months (Fig. S11, S12). Second, the empirical epidemiological studies with two or three years of monitoring 213 could match scenarios with blunting reducing vaccine effectiveness by up to 50% (Fig. 214 S22). However, such a high level of blunting could be ruled out by the 6-year study in the 215 216 UK. This indicates the need for larger sample sizes and longer monitoring to reliably 217 estimate vaccine effectiveness and the impact of new immunization programs. Third, consistent with expectation and epidemiological observations, the COVID-19 pandemic 218 219 was predicted to have a substantial impact on pertussis dynamics, with a decline in incidence followed by a rebound (e.g., Figs. S25 A&B, S27A&B, S29A&B, S31A&B, S34 A-220 D). However, the temporal dynamics of RR remained consistent in this scenario (Figs. 221 S32, S33, S34 E-H), likely because in our model control measures equally affected infants 222 223 born from vaccinated or unvaccinated mothers.

224

225 Discussion

226

227 In this study, we aimed to review the epidemiological evidence regarding the impact of 228 maternal immunization on the effectiveness of pertussis vaccines in infants. We interpret 229 this evidence using a new mechanistic mathematical model that represented the effect of blunting on pertussis transmission dynamics. Our systematic review identified four 230 231 observational epidemiological studies, which had a maximum monitoring time of 6 years and were often combined with small sample sizes. Most studies suggested a reduced risk 232 233 of pertussis after receipt of the first vaccine dose in infants born to mothers immunized 234 during pregnancy. After receipt of the second or third vaccine dose, however, the 235 estimates had large uncertainty, consistent with a range of assumptions about blunting 236 levels. To interpret these empirical estimates, we performed a simulation study using an 237 age-structured model of pertussis transmission. This model predicted that the 238 introduction of maternal immunization was followed by a transient phase lasting at least a decade, during which the blunting effect of maternal antibodies could be 239 240 underestimated. The model-data comparison suggested that a modest level of blunting could not be ruled out, even though the large uncertainty in empirical estimates 241 prevented a definitive conclusion. Even in the presence of such blunting, however, our 242 243 model predicted that maternal immunization remained effective at reducing pertussis in 244 unvaccinated newborns. Hence, our results confirm that maternal immunization is an 245 effective strategy to protect this age group, but suggest it may eventually result in an 246 infection-control trade-off with older age groups.

247

248 Unvaccinated newborns are the age group most vulnerable to pertussis, both in terms of infection and hospitalization risks^{6,7,8}. Our study suggests that, although blunting may 249 250 erode the benefits of immunization in infants, maternal immunization is highly effective 251 at protecting unvaccinated newborns. Hence, our results support the decision of many public health authorities to introduce maternal immunization against pertussis, provided 252 253 that the main control objective is to protect newborns^{9,10}. More generally, given the 254 vulnerability of newborns to many pathogens, maternal immunization against other infectious diseases is considered by public health authorities, and the pharmaceutical 255 256 industry is developing new vaccines for immunization during pregnancy. For example, a 257 maternal vaccine against RSV recently underwent successful phase 3 trial²⁹ and may soon 258 be rolled out³⁰. In addition to the Tdap and RSV vaccines, maternal immunization is

recommended or under development for influenza, COVID-19, polio and several other
infections³¹⁻³³. Maternal immunization, therefore, also appears as a promising strategy to
protect newborns against these infections, but given that immunological blunting has
been documented for many infections^{18,34-37}, our results suggest the need to monitor its
impact on subsequent vaccination of infants carefully.

264

One of the main takeaways from our review was the large uncertainty around the 265 266 available empirical estimates, emphasizing the urgent need for more research on 267 blunting. However, if such blunting is confirmed by future evidence, there are ways to 268 mitigate its impact. Immunity in newborns conferred by maternal antibodies against pertussis likely wanes quickly, on a timescale of months, according to our model. Given 269 270 the fast waning of maternal antibodies and the negative association between the 271 maternal antibody titers and the blunting of infant immune responses³⁸, delaying infant primary immunization by a few months might greatly reduce the maternal blunting of 272 273 infant immunization³⁶. Pertussis immunization schedules vary greatly between 274 countries, with the age at first immunization of infants typically ranging between two and four months³⁹, and the current variation in pertussis immunization schedule can 275 significantly impact the effectiveness of pertussis immunization in infants⁴⁰. If maternal 276 277 blunting occurs, our results suggest that the optimal age at first immunization is governed 278 by a trade-off between vaccinating too early (with the effect of reducing the susceptibility age window in newborns but amplifying the impact of blunting in vaccinated infants) and 279 280 too late (with the opposite effect). As the costs of infection in unvaccinated newborns likely exceed those in older age groups, the introduction of maternal immunization may 281 282 thus increase the optimal age at first immunization, in all infants or only in those born to vaccinated mothers. The Dutch public health authorities take an interesting approach: 283 the recommended age for the first dose of primary immunization for children from 284 285 unvaccinated mothers is two months, while for children from vaccinated mothers the recommendation is to start one month later, at three months⁴¹. Identifying the optimal 286 pertussis immunization schedule for infants would be helpful for public health 287 authorities, especially given the vast between-country variation in pertussis 288 immunization schedules^{39,40,42}. Our new model could thus help future research on 289 optimal vaccine schedules. 290

291

After the roll-out of maternal immunization, our model predicted a transient phase 292 293 lasting approximately a decade, during which the incidence of pertussis—in both unvaccinated newborns and vaccinated infants—initially dropped, but then bounced 294 295 back and increased to reach a new equilibrium. The duration of this transient phase is consistent with that found in a previous modeling study⁴³ and may be explained by the 296 297 time required for the first cohorts of blunted-vaccinated infants (*i.e.*, born to vaccinated mothers) to reach primary school age and its associated high contacts. Thus, reduced 298 299 transmission from unvaccinated newborns may explain the initial decrease in incidence 300 across age groups, but this benefit gradually wears off as blunted-vaccinated, and 301 therefore less well-protected, children age.

302

303 From a practical perspective, the transient phase following maternal immunization has 304 at least two important implications. First, the current individual-based epidemiological studies had ≤ 6 years of monitoring, which we predict is insufficient to capture the 305 306 consequences of maternal immunization that can only be detected with at least a decade of data. Second, an RR of 1 is considered the baseline value indicating that maternal 307 immunization does not blunt vaccine effectiveness in infants. In the transient phase, 308 309 however, our model predicts that the baseline value under a no-blunting scenario starts 310 off close to 0 and gradually increases to an equilibrium just below 1. This equilibrium 311 value results from the residual protection from maternal antibodies, which partially 312 compensates for failures of primary immunization in infants born to vaccinated mothers. 313 These results suggest that the early empirical estimates of vaccine effectiveness may 314 overestimate the benefits of maternal immunization, both for newborns and for infants. 315 A testable prediction of our model, therefore, is that the benefits of maternal immunization estimated in subsequent studies will be lower than those currently 316 reported, both in newborns and after the primary series. More broadly, as reflected in 317 some official guidelines for vaccine impact evaluation⁴⁴ and demonstrated for other 318 vaccines such as influenza and streptococcus, biased estimation of vaccine effectiveness 319 320 because of transient dynamics early after vaccine rollout is likely a more general 321 occurrence.

322

323 Epidemiological monitoring studies have, until now, not reported maternal
324 immunization-mediated rebounds in pertussis incidence (e.g.,⁴⁵). However, we believe

that the best way to quantify the clinical and epidemiological impact of blunting is by 325 326 more precise individual-level estimation of the RR (ideally after the transient phase 327 predicted by our model), instead of monitoring population-level changes in pertussis 328 incidence. This is for several reasons. First, we predict that the rebound a few years after 329 the roll-out of maternal immunization will be small compared to the large reduction 330 immediately after. Hence, detecting an increase in pertussis incidence resulting from maternal immunization may be difficult. Second, many countries have reported pertussis 331 resurgence in the last decades⁵, so empirical studies of pertussis incidence may face the 332 333 challenge of disentangling pre-maternal immunization increases from a post-maternal 334 immunization rebound, which is challenging especially considering the multiannual periodicity of pertussis. The interpretation of trends in pertussis incidence may be 335 336 further compounded by changes in national immunization schedules (e.g.,⁴⁰) and the impact of NPIs during the COVID-19 pandemic. For the latter, we predict that the RR will 337 remain a more robust metric. 338

339

In addition to the monitoring time, other components of the design of current 340 epidemiological studies may affect their interpretation. First, as the mothers' decision to 341 receive Tdap during pregnancy is voluntary and likely related to other socioeconomic 342 factors that will affect—and presumably reduce—their infants' risk of pertussis, the 343 344 baseline comparability between groups in these observational studies is far from obvious. Hence, estimates of the effectiveness of maternal immunization may have been 345 346 confounded by healthy user bias; interestingly, the study that controlled most thoroughly for maternal characteristics¹⁶ had large statistical uncertainty around its RR estimates 347 348 and could not rule out blunting. In addition to this confounding problem, maternal immunization may prevent mothers from transmitting pertussis to their infants, an 349 350 indirect effect that could lead to underestimating the risk of pertussis and masking the 351 effect of blunting in the group of infants vaccinated and born to vaccinated mothers (as recognized by some investigators¹³). Because of these potential biases, current RR 352 estimates may have been underestimated. Our model does not account for such potential 353 354 biases and hence our model predictions regarding the level of blunting may be 355 conservative.

356

Our study has several limitations. First, our model was parameterized based on previous 357 estimates in Massachusetts, USA, and may only correctly represent pertussis 358 359 epidemiology in comparable high-income countries. To adress this limitation, we have 360 performed sensitivity analyses with a range of basic reproduction numbers, and the conclusions were consistent. Second, in the absence of serological correlates of protection 361 for pertussis⁴⁶⁻⁴⁸, the duration of maternally-derived protection—and in particular how 362 it connects to maternal antibody titers in the infant—is unknown. In our model, this 363 364 parameter was calibrated to reach empirical estimates of maternal immunization 365 effectiveness in newborns, with an average duration of maternally derived protection at 366 8.7 months resulting in vaccine effectiveness for newborns close to 80%. Even though 367 sensitivity analyses demonstrated that our main results were robust to variations in this 368 parameter, more accurate estimation will be important to inform future models and to 369 predict optimal vaccination schedules. Third, for simplicity, we did not model the direct, protective effect of maternal immunization on mothers—only the indirect effect on their 370 371 newborns. This direct effect is an additional benefit of maternal immunization, but because in high-income countries the proportion of women giving birth is small relative 372 to the total adult population (2021 range among all EU-member states: 1.1 to 1.8 live 373 births per 1,000 individuals), it is expected to have a minor epidemiological impact. 374 Fourth, in our simulations, maternal immunization coverage was fixed at 70%, while in 375 376 real-world settings it is often initially low and takes several years to increase to the higher values described in Table S1 (e.g., Fig. 1 in¹⁴). However, such temporal variations in 377 378 immunization coverage are expected to increase the duration of the transient phase and 379 would thus reinforce our conclusions about the unreliability of early empirical estimates. 380

381 To conclude, our study shows that maternal immunization is effective at protecting 382 newborns, even when blunting erodes some of its benefits. The degree of blunting, and 383 the extent to which it entails an epidemiological cost in older age groups, can not be known yet, as we predict that the implementation of maternal immunization is followed 384 by a transient phase during which the epidemiological impact of blunting is masked. 385 Hence, current epidemiological studies may be insufficient to rule out blunting or grasp 386 387 the long-term epidemiological consequences of maternal immunization. Our results, therefore, identify the need for more research to precisely estimate the degree of blunting 388 389 after primary immunization, if any. More generally, our study supports the use of

390 maternal immunization to reduce pertussis in newborns, but suggests this strategy may391 be associated with an infection-control trade-off between different age groups.

392

393 Methods

394

395 Systematic review and meta-analysis of empirical studies on the relative risk of pertussis
396 after maternal and infant primary immunization

397

We searched the literature on Web of Science, PubMed, and Scopus on August 25, 2023. 398 399 We used the search terms "maternal immunization AND pertussis AND effectiveness OR 400 maternal vaccination AND pertussis AND effectiveness". In Web of Science, we entered 401 these terms under 'Topic', in PubMed we entered these terms under 'Title/Abstract', and 402 in Scopus under 'Article type, Abstract, Keywords'. In these three searches, we selected the publication dates from January 1, 2012, which is the first complete year with 403 404 recommended maternal immunization in any country¹⁴, until August 25, 2023. To be included in our review, studies had to provide an estimate of the relative risk (RR) of 405 pertussis in infants having received at least one dose of their primary immunization from 406 vaccinated vs. unvaccinated mothers. We selected only those studies that used 407 laboratory-confirmed diagnosis of pertussis. Because the RR of pertussis varies 408 409 substantially between doses of infant primary immunization, we selected only studies that were explicit about the number of doses of primary immunization and we excluded 410 411 those studies that pooled estimates for various doses. For studies that provided more 412 than one estimate per dose, we used all estimates provided. When studies provided 413 estimates with and without known pertussis onset dates, we chose those estimates with known onset dates. 414

415

To estimate the RR per dose of infant primary immunization, we performed the analyses in two ways, which gave consistent results. First, we estimated the weighted means of RR per dose. Second, we performed a meta-regression following⁴⁹ and as performed in⁵⁰. In brief, in both analyses, we log-transformed the RR obtained from the studies and weighted the estimates according to the inverse of the 95% CI of the RR estimate. We preferred to use RR rather than the numbers of cases⁵¹ because there are two studies in which RR estimates correct for participants' socio-demographic covariates. The meta-

regression allowed the inclusion of all doses (as a factor) into one model and to account 423 for estimates coming from the same studies by having the study identity as a random 424 425 intercept. To account for the fact that two studies were carried out in the same 426 population, we repeated the meta-regression by including the population as a random 427 intercept, which gave consistent results. We performed the meta-regression in R v. 4.2.0⁵² with the function 'brm' from the package 'brms'⁵³ using flat uninformative priors with 428 100,000 iterations, 20,000 burn-in, and a thinning of 40. Model residuals fulfilled all 429 assumptions as checked with the function 'createDHARMA' of the package 'DHARMa'⁵⁴. 430 431 Meta-analyses usually control the heterogeneity between studies and most importantly for publication bias⁴⁹, but given the low number of studies and sample sizes, this was not 432 possible here. 433

434

435 Simulation: Model schematic

436

437 We implemented an age-structured model of pertussis transmission, extending a previous model empirically validated on data from Massachusetts, USA^{4,27}. In brief, the 438 model is based on the Susceptible-Exposed-Infected-Recovery (SEIR, Fig. S1) model in 439 which pertussis vaccines can fail by (i) failure in "take" (primary vaccine failure) and (ii) 440 failure in duration (waning of vaccine protection)⁵⁵. Based on immunological evidence 441 showing an immediate reduction in the antibody response to primary vaccination^{21,22,36}. 442 443 we assumed that blunting from maternal immunization increased the probability of 444 primary vaccine failure. Previous results in⁴ found no evidence for failure in degree (or 445 leakiness, i.e., when vaccine-induced protection is imperfect and vaccinees remain 446 susceptible to infection, but at a lower degree than unvaccinated individuals), and hence we ignored this possibility. 447

448

The model is designed such that we follow individuals grouped according to their immunization history. For each immunization, individuals can go to either of three compartments: one for successful immunization, one for failed immunization, and one for immunization not received (Fig. S1). These three possible paths or compartments start from their mother's immunization status during pregnancy, followed by an infant immunization schedule that resembles that of the empirical studies in Table S1: the infant's primary immunization occurs at the age of three months, and an infant booster

456 at the age of 1.5 years. Hence, newborns can be born in three possible compartments: 457 from vaccinated mothers whose immunization succeeded, mothers whose immunization failed (i.e., who received the vaccine but whose infant remained unprotected), or 458 459 unvaccinated mothers. We model maternal immunization by transferring a fraction of newborns to a protected class. Maternal immunization in itself is not modeled; hence our 460 461 model does not specify at which stage of pregnancy maternal immunization occurs. The assumed high effectiveness of maternal immunization implies that it occurred at a timing 462 463 consistent with that used in the studies in Table S1 and in the empirical studies of the 464 systematic review, i.e., during the second or third trimester of pregnancy and at least one 465 week before giving birth.

466

467 Each of the three compartments is followed by a compartment for successful primary 468 infant immunization (Fig. S1) and a compartment for failed primary infant immunization, thereby becoming susceptible (Fig. S1), or no immunization thereby also becoming 469 470 susceptible. Following the first booster, these susceptibles become immunized again at an effectiveness of 96%, with a subsequent waning rate of vaccine protection of 0.011 yr 471 ¹ (Table S3). For simplicity, as in earlier modeling studies⁴, we model the infant primary 472 immunization as one event and we do not consider the gradual effect of multiple vaccine 473 474 doses.

475

476 Model parametrization

477

478 Parametrization of the base model

Our model is based on⁴, which was fitted to pertussis incidence data from Massachusetts
to identify the model parameters that best matched the data. Hence, for the parameters
consistent between both models, we used the estimates from⁴ (Table S3), but note that
the sensitivity analyses explained below and shown in the supplementary information
create conditions that represent other populations.

484

By adding maternal immunization to this model, we also added three new parameters. The first parameter is maternal immunization coverage, for which we use a baseline of coverage, for which we use a baseline of maternal immunization coverage, for which we use a baseline of maternal immunization (Table S1). The second parameter is the duration of maternally derived

489 immunity, for which, there are no empirical estimates. One proxy is the half-life of maternal antibodies, which ranges between 29 and 36 days^{56,57}, suggesting that the 490 491 duration of maternally-derived immunity is short. However, because of the absence of 492 definite correlates of protection⁴⁶⁻⁴⁸, the correspondence between the waning rate of maternal antibodies and that of maternal immunity is unknown. For example, if both 493 494 waning rates are assumed equal and without the transfer of new maternal antibodies, e.g., through breastfeeding, according to our model the effectiveness of maternal 495 immunization in the first two months after birth would be close to 50% (Fig. S1). This is 496 497 in contrast with the estimated effectiveness of maternal immunization in that age class, which ranged from 78% (15 95% CI: 48-90) to 93% (12 95% CI: 81-97). Thus, in our 498 499 model, we calibrated the average duration of maternal protection to reach these 500 empirical estimates of vaccine effectiveness and hence we show results with an average duration of 8.7 months (Table S3, Fig. S2). The third parameter is the blunting of infant 501 502 immune protection, defined as the relative reduction in the effectiveness of the primary 503 series in infants born to vaccinated mothers (compared to infants born to unvaccinated 504 mothers). There are no empirical estimates of the degree of blunting of infant protection following maternal immunization or how changes in IgG titers translate into changes in 505 protection. When infants receive their primary immunization, the antibody 506 concentrations of infants from vaccinated mothers are 30% to 60% lower compared to 507 508 those from unvaccinated mothers^{21,22}. To best match the empirical estimates of the relative risk of pertussis, we chose a decrease in the effectiveness of primary 509 510 immunization from 0% (i.e., no blunting) to 20%. Formally, the blunting parameter b_1 is 511 modeled as a relative reduction in the initial effectiveness of infant immunization ε_{i} resulting in a blunted effectiveness $\bar{\varepsilon} = \varepsilon (1 - b_1)$. 512

513

514 Sensitivity analyses

515 We checked the sensitivity of our results to nine model changes:

- 516 (i) maternal immunization coverage, changed from a baseline value of 70% to
 50% and to 90% (Fig. S5, S6), which is the range represented in Table S1;
- 518 (ii) infant immunization coverage, changed from a baseline value of 90% to 70%
 519 and 80% (Fig. S7, S8);
- 520 (iii) the average duration of maternal protection changed from a baseline value of
 521 8.7 months to 4 months and 1 year (Fig. S9, S10);

- (iv) the start of primary immunization, changed from a baseline value of 3 months
 to 2, 4, and 9 months (Fig. S11, S12);
- 524 (v) different social contact matrices, with that of the UK as baseline (in Figs. 4 and
 525 5) and changed to those in 7 other European countries as described in^{58,59} (Fig.
 526 \$13-\$18);
- 527 (vi) starting the maternal immunization program 60 years after the rollout of 528 primary immunization, instead of 100 years. This reflects an introduction of 529 maternal immunization during a honeymoon-mediated pertussis resurgence, 530 as was the case in many countries (Fig. S19, S20);
- (vii) blunting the effectiveness of the infant primary immunization up to 60% (Fig.
 S21, S22), instead of the baseline range of 0% to 20%;
- (viii) ±50% variations in the basic reproduction number, to model different
 transmission levels in a range of populations (Fig. S23, S24);
- the impact of the COVID-19 pandemic, modeled as 3- to 9-month period 535 (ix) 536 associated with lower vaccine coverage (20% reduction) and lower transmission (20%, 50%, or 70% reduction, as a result of social distancing 537 measures, Fig. S25-S34). This sensitivity analysis is motivated by the 538 539 observation that COVID-19-associated social distancing measures substantially decreased pertussis incidence^{60,61}. To model NPIs during the 540 COVID-19 pandemic, we followed the approach from a previous study which 541 reduced the transmission between 20% and 70% for a duration of 3 months 542 and 9 months⁶². We obtained estimates of the changes in immunization 543 coverage during the COVID-19 pandemic from three empirical studies^{63–65}. In 544 545 our model, we introduced these changes 8 years after the rollout of the maternal immunization program because that matches the 8-year lag between 546 the first maternal immunization programs and the COVID-19 NPIs in most 547 548 countries.
- 549
- 550 Estimation of relative risk of infection following maternal immunization
- 551

To connect the model outputs with the empirical estimates of relative risk (RR)^{13,14,16,17}, we calculated the risk of contracting pertussis in infants born to vaccinated mothers relative to that of infants born to unvaccinated mothers using the same approach as

in^{13,17}. These studies used the screening method following⁶⁶, in which the RR is estimated
as:

557

$$RR = \frac{PCV}{(1 - PCV)} \cdot \frac{(1 - PPV)}{PPV}$$

where PCV (proportion of cases vaccinated) is the proportion of cases in vaccinated 558 559 infants born to vaccinated mothers among all cases in infants vaccinated, and PPV is the 560 proportion of the population vaccinated, here equal to the vaccine coverage of maternal immunization. We validated the RR estimates of the simulations by setting the half-life of 561 maternally derived protection to infinity, which resulted in a RR of 0.05 in newborns and 562 matched the initial 95% effectiveness of maternal immunization against pertussis in 563 564 unvaccinated newborns fixed in the simulations (Fig. S2, Table S3). Hence, while the screening method may have several limitations in real-world settings⁶⁷, it provided 565 566 reliable estimates of vaccine effectiveness in the context of our model.

567

568 Numerical implementation

569

We represented the process model as a continuous-time Markov process, approximated via the tau-leap algorithm⁶⁸ with a fixed time step of 1 day. To compare the model outputs to empirical estimates, we also added an observation model for the RR. This was done by sampling the number of vaccinated cases born to vaccinated mothers from a Binomial distribution with probability PCV and size equal to the number of cases described in the empirical studies at the third dose (Table S1). The model was implemented and simulated using the 'pomp' package v. 4.4.3.0⁶⁹, operating in R v. 4.2.0⁵².

577

578 **References**

- 579 1. Kilgore, P. E., Salim, A. M., Zervos, M. J. & Schmitt, H. J. Pertussis: Microbiology, Disease,
- 580 Treatment, and Prevention. *Clin. Microbiol. Rev.* **29**, 449–486 (2016).
- 581 2. Rohani, P. & Scarpino, S. V. *Pertussis: Epidemiology, Immunology & Evolution*. (Oxford
 582 University Press, Oxford, 2019).
- 5833.Amirthalingam, G., Gupta, S. & Campbell, H. Pertussis immunisation and control in England
- and Wales, 1957 to 2012: a historical review. *Euro Surveill.* **18**, ii=20587 (2013).
- 585 4. Domenech de Cellès, M., Magpantay, F. M. G., King, A. A. & Rohani, P. The impact of past

586vaccination coverage and immunity on pertussis resurgence. Sci. Transl. Med. 10, eaaj1748

587 (2018).

- 588 5. Domenech de Cellès, M., Magpantay, F. M. G., King, A. A. & Rohani, P. The pertussis enigma:
- reconciling epidemiology, immunology and evolution. *Proc. Biol. Sci. B* 283, 20152309
- 590 (2016).
- 591 6. Kandeil, W. *et al.* A systematic review of the burden of pertussis disease in infants and the
- effectiveness of maternal immunization against pertussis. *Expert Rev. Vaccines* 19, 621–638
 (2020).
- 594 7. Mbayei, S. A. *et al.* Severe Pertussis Infections in the United States, 2011–2015. *Clin. Infect.*595 *Dis.* 69, 218–226 (2019).
- Section 8. Quinn, H. E. *et al.* Pertussis disease and antenatal vaccine effectiveness in Australian
 children. *Pediatr. Infect. Dis. J.* 41, 180–185 (2022).
- **598** 9. World Health Organization. Pertussis vaccines: WHO position paper August 2015. (2015).
- 599 10. Abu-Raya, B. *et al.* Global perspectives on immunization during pregnancy and priorities for
- future research and development: an international consensus statement. *Front. Immunol.* **11**, 1282 (2020).
- 602 11. Amirthalingam, G. *et al.* Effectiveness of maternal pertussis vaccination in England: an
 603 observational study. *Lancet* 384, 1521–1528 (2014).
- Dabrera, G. *et al.* A case-control study to estimate the effectiveness of maternal pertussis
 vaccination in protecting newborn infants in England and Wales, 2012–2013. *Clin. Infect. Dis.* 60, 333–337 (2015).
- 607 13. Amirthalingam, G. *et al.* Sustained effectiveness of the maternal pertussis immunization
- 608 program in England 3 years following introduction. *Clin. Infect. Dis.* **63**, S236–S243 (2016).
- 609 14. Baxter, R., Bartlett, J., Fireman, B., Lewis, E. & Klein, N. P. Effectiveness of vaccination during
 610 pregnancy to prevent infant pertussis. *Pediatrics* 139, e20164091 (2017).
- 611 15. Skoff, T. H. *et al.* Impact of the US Maternal Tetanus, Diphtheria, and Acellular Pertussis
- 612 Vaccination Program on Preventing Pertussis in Infants <2 Months of Age: A Case-Control

- 613 Evaluation. *Clin. Infect. Dis.* **65**, 1977–1983 (2017).
- 614 16. Rowe, S. L. *et al.* Maternal vaccination and infant influenza and pertussis. *Pediatrics* 148,
 615 e2021051076 (2021).
- 616 17. Amirthalingam, G. et al. Optimization of Timing of Maternal Pertussis Immunization From 6
- 617 Years of Postimplementation Surveillance Data in England. *Clin. Infect. Dis.* **8**, e1129–e1139
- **618** (2023).
- 619 18. Albrecht, P., A, E. F., Saltzman, E. J. & S, K. Persistence of maternal antibody in infants
- 620 beyond 12 months: mechanism of measles vaccine failure. *J. Pediatr.* **91**, 715–717 (1977).
- 621 19. Bento, A. I., King, A. A. & Rohani, P. Maternal pertussis immunisation: clinical gains and
 622 epidemiological legacy. *Euro Surveill.* 22, 30510 (2017).
- 623 20. Leuridan, E. Pertussis vaccination in pregnancy: State of the art. *Vaccine* 35, 4453–4456
 624 (2017).
- Barug, D. *et al.* Maternal pertussis vaccination and its effects on the immune response of
 infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised

627 controlled trial. *Lancet Infect. Dis.* **19**, 392–401 (2019).

- 628 22. Abu-Raya, B. *et al.* The effect of Tetanus-Diphtheria-Acellular-Pertussis immunization
- 629 during pregnancy on infant antibody responses: individual-participant data meta-analysis.
- 630 Front. Immunol. **12**, 689394 (2021).
- 631 23. Jones, C. E. *et al.* A phase IV, multi-centre, randomized clinical trial comparing two

632 pertussis-containing vaccines in pregnant women in England and vaccine responses in

- 633 their infants. *BMC Med.* **19**, 138 (2021).
- 634 24. Sapuan, S. *et al.* An observational, cohort, multi-centre, open label phase IV extension study
- 635 comparing preschool DTAP-IPV booster vaccine responses in children whose mothers were
- 636 randomised to one of two pertussis-containing vaccines or received no pertussis-
- 637 containing vaccine in pregnancy in England. *Vaccine* **40**, 7050–7056 (2022).
- 638 25. Caboré, R. N. et al. Influence of maternal vaccination against diphtheria, tetanus, and
- 639 pertussis on the avidity of infant antibody responses to a pertussis containing vaccine in

- 640 Belgium. *Virulence* **8**, 1245–1254 (2017).
- 641 26. Zimmermann, P. *et al.* The effect of maternal immunisation during pregnancy on infant
- 642 vaccine responses. *EClinicalMedicine* **13**, 21–30 (2019).
- 643 27. Domenech de Cellès, M., Rohani, P. & King, A. A. Duration of Immunity and Effectiveness of
- 644Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children. JAMA Pediatr. 173, 588–594
- 645 (2019).
- 646 28. McLean, A. R. & Anderson, R. M. Measles in developing countries Part I. Epidemiological
 647 parameters and patterns. *Epidemiol. Infect.* **100**, 111–133 (1988).
- 648 29. Kampmann, B. *et al.* Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in
 649 Infants. *N. Engl. J. Med.* 388, 1451–1464 (2023).
- 650 30. Venkatesan, P. First RSV vaccine approvals. *Lancet Microbe* **4**, e577 (2023).
- 651 31. Omer, S. B. Maternal Immunization. *N. Engl. J. Med.* **376**, 1256–1267 (2017).
- 652 32. Halasa, N. B. *et al.* Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine
- 653During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months</th>
- 654 17 States, July 2021-January 2022. *MMWR Morb. Mortal. Wkly. Rep.* **71**, 264–270 (2022).
- 655 33. Etti, M. *et al.* Maternal vaccination: a review of current evidence and recommendations. *Am.*
- 656 *J. Obstet. Gynecol.* **226**, 459–474 (2022).
- Gans, H. A. *et al.* Deficiency of the Humoral Immune Response to Measles Vaccine in Infants
 Immunized at Age 6 Months. *JAMA* 280, 527–532 (1998).
- 35. Mawa, P. A. *et al.* The impact of maternal infection with Mycobacterium tuberculosis on the
 infant response to bacille Calmette–Guérin immunization. *Philos. Trans. R. Soc. Lond. B Biol.*
- 661 *Sci.* **3017**, 20140137 (2015).
- 662 36. Voysey, M. *et al.* The influence of maternally derived antibody and infant age at vaccination
- on infant vaccine responses: an individual participant meta-analysis. *JAMA Pediatr.* 17,
 664 637–646 (2017).
- Grassly, N. C. *et al.* Effect of maternal immunisation with multivalent vaccines containing
 inactivated poliovirus vaccine (IPV) on infant IPV immune response: A phase 4, multi-

- 667 centre randomised trial. *Vaccine* **41**, 1299–1302 (2023).
- 668 38. Abu-Raya, B. *et al.* Factors affecting antibody responses to immunizations in infants born to
- 669 women immunized against pertussis in pregnancy and unimmunized women: Individual-
- 670 Participant Data Meta-analysis. *Vaccine* **39**, 6545–6552 (2021).
- 671 39. Perkins, T. A. & Tran, Q. M. Timing is everything when it comes to pertussis vaccination.
- 672 *Lancet Infect. Dis.* **22**, 158–159 (2022).
- 40. Paireau, J. *et al.* Impact of vaccine schedule change on pertussis epidemiology in France: a
 modelling and serological study. *Lancet Infect. Dis.* 22, 265–273 (2022).
- 675 41. Rijksinstituut_Voor_Volksgezondheid_en_Milieu. Rijksinstituut voor Volksgezondheid en
- 676 Milieu. Dutch National Immunisation Programme
- 677 https://rijksvaccinatieprogramma.nl/english.
- 42. Riolo, M. A. & Rohani, P. Combating pertussis resurgence: One booster vaccination schedule
- 679 does not fit all. *Proc. Natl. Acad. Sci. U. S. A.* **112**, E472–E477 (2015).
- 680 43. Bento, A. I. & Rohani, P. Forecasting Epidemiological Consequences of Maternal
- 681 Immunization. *Clin. Infect. Dis.* **63**, S205–S212 (2016).
- 682 44. World Health Organization. *Measuring impact of streptococcus pneumoniae and*
- 683 *haemophilus influenzae type b conjugate vaccination.* (2012).
- 45. Skoff, T. H., Deng, L., Bozio, C. H. & Hariri, S. US Infant Pertussis Incidence Trends Before and
- After Implementation of the Maternal Tetanus, Diphtheria, and Pertussis Vaccine. *JAMA Pediatr.* In press (2023).
- 46. Van Rie, A., Wendelboe, A. M. & Englund, J. A. Role of maternal pertussis antibodies in
 infants. *Pediatr. Infect. Dis. J.* 24, S62–S65 (2005).
- 689 47. Diavatopoulos, D. A. *et al.* PERISCOPE: road towards effective control of pertussis. *Lancet*690 *Infect. Dis.* 19, e179–e186 (2019).
- 691 48. Chen, Z. *et al.* Evaluation of serum anti-pertussis toxin IgA antibodies for the diagnosis of
- Bordetella pertussis infection in young children. J. Infect. Public Health 16, 1167–1173
- 693 (2023).

- 49. Nakagawa, S. & Santos, E. S. A. Methodological issues and advances in biological meta-
- 695 analysis. *Evol. Ecol.* **26**, 1253–1274 (2012).
- 696 50. Kärkkäinen, T., Briga, M., Laaksonen, T. & Stier, A. Within-individual repeatability in
- 697telomere length: A meta-analysis in nonmammalian vertebrates. *Mol. Ecol.* **31**, 6339–6359
- **698** (2022).
- 51. Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. *J. Stat. Softw.* 36,
 1–48 (2010).
- 701 52. R Core Team. *R: A Language and Environment for Statistical Computing*. https://www.R702 project.org/ (2022).
- **703** 53. Bürkner, P.-C. brms: An R Package for Bayesian Multilevel Models Using Stan. *J. Stat. Softw.*
- **80**, 1–28 (2017).
- 54. Hartig, F. DHARMa: Residual Diagnostics for Hierarchical (Multi-Level / Mixed) Regression
 Models. R package version 0.4.6. http://florianhartig.github.io/DHARMa/ (2022).
- 707 55. McLean, A. R. & Blower, S. M. Imperfect vaccines and herd immunity to HIV. *Proc. R Soc B*708 *Biol. Sci.* 253, 9–13 (1993).
- 56. Healy, C. M. *et al.* Kinetics of maternal pertussis-specific antibodies in infants of mothers
- 710 vaccinated with tetanus, diphtheria and acellular pertussis (Tdap) during pregnancy.
- 711 *Vaccine* **38**, 5955–5961 (2020).
- 712 57. Oguti, B. *et al.* The half-life of maternal transplacental antibodies against diphtheria,
- tetanus, and pertussis in infants: an individual participant data meta-analysis. *Vaccine* **40**,
- 714 450–458 (2022).
- 58. Mossong, J. *et al.* Social contacts and mixing patterns relevant to the spread of infectious
 diseases. *PLoS Med.* 5, e74 (2008).
- **717 59.** Béraud, G. *et al.* The French Connection: The First Large Population-Based Contact Survey
- in France Relevant for the Spread of Infectious Diseases. *PLoS One* **10**, e0133203 (2015).
- 60. Tessier, E. *et al.* Impact of the COVID-19 pandemic on Bordetella pertussis infections in
- 720 England. *BMC Public Health* **22**, 405 (2022).

- 721 61. Reicherz, F., Golding, L., Lavoie, P. M. & Abu-Raya, B. Decay of anti-Bordetella pertussis
- antibodies in women of childbearing age following COVID-19 non-pharmaceutical

723 measures. *Vaccine* **40**, 3746–3751 (2022).

- 62. Brett, T. S. & Rohani, P. Transmission dynamics reveal the impracticality of COVID-19 herd
- 725 immunity strategies. *Proc. Natl. Acad. Sci. U. S. A.* **117**, 25897–25903 (2020).
- 63. Causey, K. et al. Estimating global and regional disruptions to routine childhood vaccine
- coverage during the COVID-19 pandemic in 2020: a modelling study. *Lancet* **398**, 522–534
- 728 (2021).
- 64. Kim, S., Headley, T. Y. & Tozan, Y. Universal healthcare coverage and health service delivery
- before and during the COVID-19 pandemic: A difference-in-difference study of childhood
- immunization coverage from 195 countries. *PLoS Med.* **19**, e1004060 (2022).
- 65. Lai, X. *et al.* Estimating global and regional between-country inequality in routine childhood
- vaccine coverage in 195 countries and territories from 2019 to 2021: a longitudinal study.
- 734 *EClinicalMedicine* **60**, 102042 (2023).
- Farrington, C. P. Estimation of vaccine effectiveness using the screening method. *Int. J. Epidemiol.* 22, 742–746 (1993).
- 67. Minodier, L. *et al.* Influenza vaccine effectiveness: best practice and current limitations of
 the screening method and their implications for the clinic. *Expert Rev. Vaccines* 13, 1039–
 1048 (2014).
- 68. He, D., Ionides, E. L. & King, A. A. Plug-and-play inference for disease dynamics: measles in
 large and small populations as a case study. *J. R. Soc. Interface* 7, 271–283 (2010).
- King, A. A., Nguyen, D. & Ionides, E. L. Statistical Inference for Partially Observed Markov
 Processes via the R Package pomp. *J. Stat. Softw.* 69, 1–43 (2016).
- 744 70. Page, M. J. *et al.* The PRISMA 2020 statement: an updated guideline for reporting systematic
 745 reviews. *BMJ* 372, n71 (2021).

746

747 Acknowledgements

- 748 We thank the useful discussions and feedback from Andrew Tredennick (University of
- 749 Georgia, USA), Christian Gunning (University of Georgia, USA), Denis Macina (Sanofi
- 750 Pasteur, France), Laurent Coudeville (Sanofi Pasteur, France), and Edward Thommes
- 751 (Sanofi Pasteur, Canada).
- 752

753 Data Reproducibility

- 754 All R scripts are currently available at:
- 755 <u>https://drive.google.com/drive/folders/1-tT3XaPYwPbviXe10B7 hvN8SSYe9HYJ</u>, and
- will be made freely available upon publication via Edmond, the Open Data Repository of
- 757 the Max Planck Society.
- 758

759 Potential conflict of interests

760 Prof. Pejman Rohani received funding from Sanofi France for another separate project.



761

Fig. 1 Prisma flow chart, following⁷⁰, of the literature search for empirical estimates of the 762

763 relative risk (RR) of contracting pertussis following maternal immunization in children

who had received at least one dose of infant primary immunization. 764



765

Fig. 2 Overview of the results from empirical epidemiologic studies of the relative risk of contracting pertussis after 1–3 vaccine doses for primary immunization in infants from vaccinated mothers relative to those of unvaccinated mothers during infant primary immunization. The literature search protocol is shown in Fig. 1, and the data are available in Table S1. The two lines for the UK 3-year study represent two estimates of maternal immunization coverage. References: Australia 2 yrs¹⁶, California 6 yrs¹⁴, UK 3 yrs¹³, and UK 6 yrs¹⁷.





Fig. 3 Illustration of honeymoon effects and transient susceptible dynamics following the
start of infant immunization (vertical dashed line at time = 0 years) and maternal
immunization without blunting (vertical dashed line at time = 100 years) showing (A)
pertussis incidence and (B) the fraction susceptible for each age class from one stochastic
simulation.





780 Fig. 4 Model predictions of the consequences of maternal immunization and blunting for pertussis incidence in (A) unvaccinated newborns (aged 0-2 mo) and (B) vaccinated 781 infants (aged 3–18 mo, after receipt of primary immunization). For this age class, during 782 the transient phase after maternal immunization, pertussis incidence is at first mostly 783 784 driven by (C) infants from unvaccinated mothers until (D) pertussis incidence is most 785 abundant in infants from vaccinated mothers. Panel (D) is consistent with the PCV-term in the RR equation (see methods, ⁶⁶). Solid lines show the median incidence of 100 786 simulations and shaded areas represent the 95% CI. Pertussis incidence before the start 787 788 of the maternal immunization program is shown as a control, and variation in incidence 789 between simulations is the result of demographic stochasticity. In this figure, all 790 immunization coverages were set at 70%, which is close to the mean observed values in 791 empirical studies (e.g., Table S1). Note the different y-axis between panels.

779



793 Fig. 5 Temporal dynamics of the risk of contracting pertussis in (A) unvaccinated 794 newborns and (B, C) vaccinated infants from vaccinated mothers relative to those of unvaccinated mothers.. (A, B) Solid lines show the median RR of 100 simulations and 795 796 shaded areas show 95% CI resulting from demographic stochasticity across simulations. 797 (C) Comparison between the results from model simulations (gradient red diamonds) 798 and the empirical studies (colored dots). In simulations, vertical lines show 95% CI due 799 to demographic stochasticity and observation uncertainty, resulting from the partial 800 sampling of the population with sample sizes matching those from empirical studies in 801 Fig. 2 (Table S1).

32